CRS investment performance: YTD through July 6.2%; 12‑month 13.3%; August adds 1.3%

Marquette's monthly report showed a year‑to‑date return of 6.2% through July 31 and a 12‑month return of 13.3%. The board heard that, while performance has generally outpaced relevant benchmarks, the year‑to‑date figure through July remained below the actuary's 7.5% assumed return.

The director provided an immediate update saying August was a positive month (+1.3%), which he said brought year‑to‑date performance to 8.4% and exceeded both the target benchmark and the actuary's 7.5% assumed return. Trustees were told staff will bring recommendations in November to increase allocations in private debt and private equity to move closer to target allocations; staff also expects to finalize the PeakVue contract and proceed with Accolade LPA steps in the coming months.

Trustees did not take new investment votes at this meeting; the presentation was informational and followed by planning steps for manager agreements and target rebalancing.